SEOUL, South Korea, Oct. 27 /PRNewswire/ -- Dong-A Pharmaceutical Co., Ltd., announced that Zydena, its new oral tablet for erectile dysfunction (ED) will be distributed in Saudi Arabia, Oman, Bahrain, Kuwait, UAE and Qatar under a supply and distribution agreement with SCP. This new agreement with SCP will position Zydena to effectively compete in this region with Viagra(R) (Pfizer), Cialis(R) (Lilly) and Levitra(R) (Bayer).
Zydena was launched in Korea in December of 2005 and has already exceeded more than 20%(by volume) of the Korean market due to its excellent efficacy and safety profile.
Dr. Won-Bae Kim, the President of Dong-A Pharmaceutical, stated that “We are extremely pleased with this new supply and distribution agreement with SCP. We are confident that this new relationship in the Middle East will significantly expand our market for Zydena and add to the success that we have already experienced in Korea. Zydena sales in Korea have been strong due to its superior efficacy, low adverse event rate and patient preferred long duration.
The Arabic pronunciation of Zydena, “give me more,” is expected to enhance brand recognition of Zydena in the Middle Eastern market.
The development of Zydena for the USA market by Dong-A PharmTech Co. Ltd, is continuing. A phase IIb clinical study for ED was recently completed 340 patients. Results of this study are expected in December, 2006.
About Dong-A Pharmaceutical Co., Ltd.
Dong-A Pharmaceutical Co., Ltd., founded in 1932 is the largest drug company in Korea. It is listed on the Korean stock exchange.
About Dong-A PharmTech Co., Ltd
Dong-A PharmTech Co., Ltd. is an affiliate of Dong-A Pharmaceutical Co., Ltd. and has rights to oversee non-Korean development programs for this unique compound.
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.
Contact: Mr. Chan Won OH General Manager, International Product Development Team 252, Yongdu-Dong, Dongdaemun-Ku Seoul 130-078, Korea Tel: +82 2 920 8220 Fax: +82 2 925 4026 Email: ocw@donga.co.kr
Dong-A Pharmaceutical Co., Ltd.
CONTACT: Mr. Chan Won OH, General Manager, International ProductDevelopment Team, of Dong-A Pharmaceutical Co., Ltd., Tel: +82 2 920 8220,or Fax: +82 2 925 4026, or Email: ocw@donga.co.kr
